How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,424 results for

Ventricular Fibrillation Management in the Child

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ventricular Fibrillation Management in the Child

Ventricular Fibrillation Management in the Child Ventricular Fibrillation Management in the Child Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Ventricular Fibrillation Management in the Child Ventricular Fibrillation Management in the Child Aka: Ventricular Fibrillation Management in the Child From Related Chapters II. Management: Approach CPR until available Good quality are critical for survival ( ) Consider 5 cycles CPR (2 min) before defibrillating options (single shock) Manual First: 2-4 J/kg Subsequent: 4 J/kg Maximum: 10 J/kg or up to adult dose AED (age 1 year or older) Child system is preferred if available ages 1-8 Secure

2018 FP Notebook

2. Atrial fibrillation: management

ablation for atrial fibrillation in association with other cardiac surgery (NICE interventional procedure guidance 121). [8] Factors indicating a high risk of atrial fibrillation recurrence include: a history of failed attempts at cardioversion; structural heart disease (mitral valve disease, left ventricular dysfunction or an enlarged left atrium); a prolonged history of atrial fibrillation (more than 12 months); previous recurrences of atrial fibrillation. Atrial fibrillation: management (CG180) © (...) Atrial fibrillation: management Atrial fibrillation: management Atrial fibrillation: management Clinical guideline Published: 18 June 2014 nice.org.uk/guidance/cg180 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response

Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response (FAARV) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

4. Identification of Ventricular Fibrillation and Optimization of Defibrillation During CPR

Identification of Ventricular Fibrillation and Optimization of Defibrillation During CPR Identification of Ventricular Fibrillation and Optimization of Defibrillation During CPR - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Identification of Ventricular Fibrillation and Optimization of Defibrillation During CPR (IVFOD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02952105 Recruitment Status : Unknown Verified October 2016 by The First Affiliated Hospital of Henan University of Science

2016 Clinical Trials

5. Ventricular Fibrillation Management in the Child

Ventricular Fibrillation Management in the Child Ventricular Fibrillation Management in the Child Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Ventricular Fibrillation Management in the Child Ventricular Fibrillation Management in the Child Aka: Ventricular Fibrillation Management in the Child From Related Chapters II. Management: Approach CPR until available Good quality are critical for survival ( ) Consider 5 cycles CPR (2 min) before defibrillating options (single shock) Manual First: 2-4 J/kg Subsequent: 4 J/kg Maximum: 10 J/kg or up to adult dose AED (age 1 year or older) Child system is preferred if available ages 1-8 Secure

2015 FP Notebook

6. Management of Atrial Fibrillation

(ACS), aggravation of heart failure, thrombo-embolic complications, and acute arrhythmia management are the main causes. Quality of life and exercise capacity are degraded in patients with AF. 9 This may be related to impaired left ventricular (LV) function that accompanies the irregular, fast ventricular rate, loss of atrial contractile function and increased end-diastolic LV ?lling pressure. 2 Adapted from the ESC Guidelines for the Management of Atrial Fibrillation (2010 Version) (European heart (...) for cardiac arrhythmias. Acute Coronary Syndrome (ACS), aggravation of heart failure, thrombo-embolic complications, and acute arrhythmia management are the main causes. Quality of life and exercise capacity are degraded in patients with AF. 9 This may be related to impaired left ventricular (LV) function that accompanies the irregular, fast ventricular rate, loss of atrial contractile function and increased end-diastolic LV ?lling pressure. Figure 2 : ‘Natural’ time course of AF. AF = atrial fibrillation

2012 Ministry of Health, Malaysia

7. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation 2017 www.kce.fgov.be KCE REPORT 279 ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION 2017 www.kce.fgov.be KCE REPORT 279 HEALTH TECHNOLOGY ASSESSMENT ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION HANS VAN BRABANDT, LORENA SAN MIGUEL, NICOLAS FAIRON, BERT VAES, SEVERINE HENRARD, ANELIA BOSHNAKOVA, ROB COOK, ROB DAVIES, ADITI KARNAD, ALAN LOVELL, CECILE DUBOIS COLOPHON Title: Anticoagulants in non-valvular atrial fibrillation Authors: Hans (...) responsibility of the KCE. Publication date: 9 januari 2017 Domain: Health Technology Assessment (HTA) MeSH: atrial fibrillation; anticoagulants; secondary prevention; Belgium; cost-benefit analysis; Practice Patterns, Physicians'; Practice Guidelines as Topic NLM Classification: QV 193 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2016/10.273/101 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce

2017 Belgian Health Care Knowledge Centre

8. 2017 Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: A Joint Consensus Document from EHRA and ESC Working Group on Thrombosis

) EHRA Type 2 VHD, which refers to AF patients with ‘VHD needing therapy with a VKA or a Non-VKA oral anticoagulant (NOAC)’, also taking into consideration CHA 2 DS 2 VASc score risk factor components. This consensus document also summarizes current developments in the field, and provides general recommendations for the management of these patients based on the principles of evidence-based medicine. , , , , , , , , , , Preamble and valvular heart disease definition Atrial fibrillation (AF) is a major (...) ). One small pilot study compared Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively (DAWA Pilot Study) but small numbers preclude definitive conclusions. Recent small studies also suggest that NOACs can be a reasonable alternative to VKA in patients with AF and remote bioprosthetic valve implantation, , however larger studies are needed to define the safety and efficacy profile. Data on thromboprophylaxis in patients with AF

Full Text available with Trip Pro

2017 Heart Rhythm Society

9. Mitral valve replacement in a child during active rheumatic carditis: successful management of sixteen episodes of ventricular fibrillation. (PubMed)

Mitral valve replacement in a child during active rheumatic carditis: successful management of sixteen episodes of ventricular fibrillation. 4224485 1967 02 05 2018 11 13 0003-4932 164 6 1966 Dec Annals of surgery Ann. Surg. Mitral valve replacement in a child during active rheumatic carditis: successful management of sixteen episodes of ventricular fibrillation. 1034-40 Timmis H H HH Hardy J D JD Watson D G DG Blake T M TM eng Case Reports Journal Article United States Ann Surg 0372354 0003 (...) -4932 AIM IM Angiocardiography Cardiomegaly Child Electric Countershock Electrocardiography Female Heart Arrest Heart Failure surgery Heart Valve Prosthesis Humans Mitral Valve surgery Postoperative Care Postoperative Complications Rheumatic Fever surgery Ventricular Fibrillation therapy 1966 12 1 1966 12 1 0 1 1966 12 1 0 0 ppublish 4224485 PMC1477218 Ann Intern Med. 1962 Mar;56:367-88 13919640 Pediatrics. 1964 Apr;33:571-8 14166538 AMA Am J Dis Child. 1955 Jan;89(1):7-14 13217451

Full Text available with Trip Pro

1966 Annals of Surgery

10. Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests the Superiority of Right Ventricular Bifocal Stimulation Over VVI Implantable Defibrillator in Right Bundle Branch Block and He

Block and Heart Failure. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests (...) At least fifty patients would be enrolled. The enrollment period should be one year. Study overall duration should be two years. ELIGIBILITY CRITERIA RBBB and HFrEF (left ventricular ejection fraction ≤35%) in sinus rhythm, in NYHA class II-III or ambulatory IV despite OMT. EXCLUSION CRITERIA -Refusal or withdrawal of informed consent.Renal failure (glomerular filtration rate ≤ 60 ml/min).Life expectancy < 12 months.Active neoplasm.Permanent atrial fibrillation.40 days following acute coronary

2018 Clinical Trials

11. Serial Multiparametric Evaluation of Right Ventricular Function After Left Ventricular Assist Device Implantation

Serial Multiparametric Evaluation of Right Ventricular Function After Left Ventricular Assist Device Implantation Serial Multiparametric Evaluation of Right Ventricular Function After Left Ventricular Assist Device Implantation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) ventricular assist device (LVAD) implantation, using novel echocardiographic quantification of RV size and function in combination with comprehensive hemodynamic, laboratory and clinical parameters. The findings of the study will enhance prediction of early and late development of postoperative right-sided heart failure (RHF) and subsequent mortality and morbidity. The secondary purpose of the study is to combine echocardiographic, hemodynamic, laboratory, and clinical data to define optimal management

2018 Clinical Trials

12. Guidelines on Supraventricular Tachycardia (for the management of patients with)

for the management of atrioventricular nodal re-entrant tachycardia 30 Recommendations for the therapy of atrioventricular re-entrant tachycardia due to manifest or concealed accessory pathways 36 Recommendations for the acute therapy of pre-excited atrial fibrillation 37 Recommendations for the management of patients with asymptomatic pre-excitation 39 Recommendations for the therapy of supraventricular tachycardias in congenital heart disease in adults 42 Recommendations for the therapy of supraventricular (...) Ventriculoatrial VT Ventricular tachycardia WL Wavelength WPW Wolff−Parkinson−White 1 Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health

Full Text available with Trip Pro

2019 European Society of Cardiology

13. Management of Dyslipidaemias

Management of Dyslipidaemias 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close (...) mobile search navigation Article Navigation Article Contents Article Navigation 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk : The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) François Mach Chairperson Switzerland Corresponding authors: François Mach, Cardiology Department, Geneva University Hospital, 4 Gabrielle-Perret-Gentil, 1211 Geneva

Full Text available with Trip Pro

2019 European Society of Cardiology

14. Guidelines on Diagnosis and Management of Syncope

nurse specialist 1935 10. Key messages 1936 11. Gaps in evidence and areas for future research 1937 12. ‘What to do’ and ‘what not to do’ messages from the Guidelines 1938 13. Supplementary Data and Web Practical Instructions 1940 14. Appendix 1940 15. References 1941 Abbreviations and acronyms Abbreviations and Acronyms Abbreviations and Acronyms ABPM Ambulatory blood pressure monitoring AF Atrial fibrillation ARVC Arrhythmogenic right ventricular cardiomyopathy ATP Adenosine triphosphate AV (...) pseudosyncope RCT Randomized controlled trial SCD Sudden cardiac death SNRT Sinus node recovery time SU Syncope unit SUP Syncope Unit Project SVT Supraventricular tachycardia TIA Transient ischaemic attack t.i.d. Ter in die (three times daily) TLOC Transient loss of consciousness TNG Trinitroglycerin VA Ventricular arrhythmia VF Ventricular fibrillation VT Ventricular tachycardia VVS Vasovagal syncope 1. Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health

Full Text available with Trip Pro

2018 European Society of Cardiology

15. Management of Stroke in Neonates and Children

Management of Stroke in Neonates and Children Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 February 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article , MD, MS, FAHA, Co (...) for the mentioned proteins in the neonatal period may be misleading and requires repeat testing for a confirmatory diagnosis. Magnetic resonance imaging (MRI) should be performed to diagnose the stroke. Magnetic resonance angiography (MRA) and magnetic resonance venography (MRV) also should be performed, especially when venous thrombosis is suspected. Management Supportive care measures for AIS in neonates include the control of seizures, the optimization of oxygenation, and the correction of dehydration

Full Text available with Trip Pro

2019 American Heart Association

16. AIM Clinical Appropriateness Guidelines for Sleep Disorder Management

heart failure (CHF) – New York Heart Association (NYHA) class III or IV 4. CHF with a history of ventricular fibrillation or sustained ventricular tachycardia in a patient who does not have an implanted defibrillator 5. Cognitive impairment (inability to follow simple instructions) resulting in inability to apply the home sleep testing equipment when another individual is not available to assist with this task 6. Physical impairment resulting in inability to apply the home sleep testing equipment (...) AIM Clinical Appropriateness Guidelines for Sleep Disorder Management Sleep Disorder Management Diagnostic & Treatment Guidelines Clinical Appropriateness Guidelines Effective Date: January 2 7, 2019 Proprietary Date of Origin: 05/04/2012 Last revised: 04/12/2018 Last reviewed: 04/12/2018 Copyright © 2019. AIM Specialty Health. All Rights Reserved Clinical & Regulatory Guidelines 8600 W Bryn Mawr Avenue South Tower - Suite 800 Chicago, IL 60631 P. 773.864.4600

2019 AIM Specialty Health

17. ESC/ESH Management of Arterial Hypertension

obstructive pulmonary disease3084 8.14 Hypertension and heart disease3084 8.14.1 Coronary artery disease3084 8.14.2 Left ventricular hypertrophy and heart failure3085 8.15 Cerebrovascular disease and cognition3086 8.15.1 Acute intracerebral haemorrhage3086 8.15.2 Acute ischaemic stroke3086 8.15.3 Previous stroke or transient ischaemic attack3086 8.15.4 Cognitive dysfunction and dementia3087 8.16 Hypertension, atrial fibrillation, and other arrhythmias3087 8.16.1 Oral anticoagulants and hypertension3088 (...) artery disease Atrial fibrillation BSA = body surface area; CAD = coronary artery disease; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HDL-C = HDL cholesterol; HFpEF = heart failure with preserved ejection fraction; HMOD = hypertension-mediated organ damage; LV = left ventricular; LVH = left ventricular hypertrophy; PWV = pulse wave velocity; SCORE = Systematic COronary Risk Evaluation; TIA

Full Text available with Trip Pro

2018 European Society of Cardiology

18. Management of Cardiovascular Diseases during Pregnancy

regurgitation 3191 6.2.2 Tricuspid regurgitation 3191 6.3 Atrial fibrillation in native heart valve disease 3191 6.4 Prosthetic valves 3191 6.4.1 Choice of valve prosthesis 3191 6.4.2 Pregnancy risk with bioprostheses 3192 6.5 Mechanical prostheses and anticoagulation 3192 6.5.1 Maternal risk 3192 6.5.2 Obstetric and offspring risk 3192 6.5.3 Management 3193 6.6 Recommendations 3195 7. Coronary artery disease 3197 7.1 Aetiology 3197 7.2 Presentation and diagnosis 3197 7.3 Management 3197 7.4 Pharmacotherapy (...) pregnancy 3199 8.3.2 Bromocriptine and peripartum cardiomyopathy 3201 8.3.3 Devices and transplantation 3201 8.3.4 Anticoagulation 3201 8.3.5 Delivery and breastfeeding 3201 8.4 Hypertrophic cardiomyopathy 3201 8.4.1 Management 3201 8.4.2 Delivery 3202 8.5 Recommendations 3202 9. Arrhythmias 3203 9.1 Introduction 3203 9.2 Maternal risk 3203 9.3 Obstetric and offspring risk 3203 9.4 Supraventricular tachycardia 3203 9.5 Atrial fibrillation and atrial flutter 3203 9.5.1 Anticoagulation 3203 9.6

Full Text available with Trip Pro

2018 European Society of Cardiology

19. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures

such techniques, to provide the level of monitoring described in these guidelines, and to manage complications of these techniques (ie, to be able to rescue the patient). Because the level of intended sedation may be exceeded, the practitioner must be sufficiently skilled to rescue a child with apnea, laryngospasm, and/or airway obstruction, including the ability to open the airway, suction secretions, provide CPAP, and perform successful bag-valve-mask ventilation should the child progress to a level of deep (...) (or APLS) and capable of managing any airway, ventilatory, or cardiovascular emergency event resulting from the deep sedation and/or general anesthesia. The independent observer must be trained and skilled to establish intravenous access and draw up and administer rescue medications. The independent observer must have the training and skills to rescue a nonbreathing child; a child with airway obstruction; or a child with hypotension, anaphylaxis, or cardiorespiratory arrest, including the ability

2019 American Academy of Pediatrics

20. Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing

Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing (SIMPLER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>